uniQure is a world leader in the research and early development of human gene based therapies. Its lead product, Glybera, for the treatment of lipoprotein lipase deficiency was approved by the European Commission in November, 2012. Glybera is the first gene therapy approved in the Western world. uniQure has a product pipeline with several gene therapies: for hemophilia B, acute intermittent porphyria, Parkinson’s disease and Sanfilippo B. uniQure is based in Amsterdam, the Netherlands. The company employs a staff with extensive scientific and industry experience, and is the world leader in manufacturing of AAV-based products on a commercial scale, meeting cGMP requirements, and has extensive experience in the regulatory process for gene therapies.